0001437749-23-000750.txt : 20230109 0001437749-23-000750.hdr.sgml : 20230109 20230109190043 ACCESSION NUMBER: 0001437749-23-000750 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230109 DATE AS OF CHANGE: 20230109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Phillips Geraint CENTRAL INDEX KEY: 0001960665 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 23519339 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA, #310 CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 3 1 rdgdoc.xml FORM 3 X0206 3 2023-01-03 0 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001960665 Phillips Geraint C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 SVP, Global Operations Common Stock 38362 D Restricted Stock Award 0.0000 Common Stock 9346 D The amount represented in Column 2 of Table I includes 24,969 shares of the Company's common stock, 4,047 shares of restricted stock granted on August 9, 2021 pursuant to the BioLife Solutions 2013 Performance Incentive Plan, as amended (the "Plan"), which vests in equal quarterly installments, and 9,346 shares of restricted stock granted on February 24, 2022 pursuant to the Plan which vests in equal quarterly installments. The restricted stock was granted pursuant to the Plan on February 24, 2022. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 3 of Table II based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. /s/ Geraint Phillips 2023-01-09